To include your compound in the COVID-19 Resource Center, submit it here.

Qnexa phentermine/topiramate regulatory update

Vivus said it is considering excluding women of child-bearing potential from the proposed label of obesity candidate Qnexa phentermine/topiramate when the company resubmits an NDA to FDA in

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE